Tsingke Biotech Hosts Shanghai Salon on Oligonucleotide Drugs, Spotlighting Next-Gen RNA Therapeutics
SHANGHAI, June 30, 2026 /PRNewswire/ -- Tsingke Biotech recently hosted the Oligonucleotide Drug Salon at the Hilton Shanghai Zhangjiang, bringing together experts from academia, biopharmaceutical companies, investment firms, and industry service organizations to discuss technological innovation, CMC development, delivery technologies, regulatory strategies, and commercialization pathways in the rapidly evolving field of oligonucleotide therapeutics. As momentum in the global...
New Human Study in Nature’s Scientific Reports Finds Candela’s Nordlys® Non-Ablative Fractional Laser Reverses the Skin’s Epigenetic Signature of Aging
First in vivo human evidence that Candela's Nordlys laser remodels DNA methylation associated with skin aging and has a direct molecular link to skin cancer biology MARLBOROUGH, Mass., June 30, 2026 /PRNewswire/ -- A new peer-reviewed study published today in Scientific Reports (Nature Portfolio) provides the first in vivo human evidence that Candela's Nordlys 1940 nm non-ablative fractional laser modulates...
Shantha Biologics Announces Cartridge Fill-Finish Collaboration
HYDERABAD, India, June 30, 2026 /PRNewswire/ -- Shantha Biologics today announced that it has entered into an outsourcing agreement with Novo Nordisk to provide cartridge fill-finish manufacturing services in India. The agreement with Novo Nordisk reflects Shantha Biologics' continued focus on high-quality manufacturing execution and its role as a trusted partner to global...
Bota Biosciences and BASF Introduce Bio-Identical Collagen III Powered by AI
PULNOY, France and HANGZHOU, China, June 30, 2026 /PRNewswire/ -- Bota Biosciences and BASF jointly announced the market launch of BASF's SkinNexus™ Collag3n. This 100% human-identical recombinant Collagen III fragment was developed in collaboration between the two companies and is being commercialized by BASF for the personal care market. The ingredient made its global debut at in-cosmetics Global...
Samsung Biologics Releases 2026 ESG Report, Highlighting Progress in Sustainable Operations and Responsible Growth
Advanced environmental performance through renewable energy transition and enhanced carbon transparency Strengthened sustainability management and supply chain engagement across the healthcare value chain INCHEON, South Korea, June 30, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), published its annual environmental, social, and governance...
CU Medicine Ranked World No. 2 in Gastroenterology & Hepatology
HONG KONG, June 30, 2026 /PRNewswire/ -- U.S. News & World Report has again ranked The Chinese University of Hong Kong (CUHK)'s Faculty of Medicine (CU Medicine) No. 2 globally in Gastroenterology & Hepatology, maintaining a top-three position worldwide for four consecutive editions. The Faculty has also been crowned Asia's No....
METiS TechBio and Boulevard Bio Enter Global License Agreement for Trispecific T-cell Engager
HONG KONG and NEW YORK, June 30, 2026 /PRNewswire/ -- METiS TechBio (7666.HK), a leading AI-driven drug delivery innovation company, today announced it has entered into an exclusive global licensing agreement with Boulevard Bio ("Boulevard"), a U.S. biotechnology company backed by Deerfield Management, granting Boulevard worldwide development, manufacturing, and commercialization rights...
WuXi Biologics Receives Brazil ANVISA GMP Certification to Enable Global Commercial Manufacturing of Innovative Cancer Immunotherapy
WUXI, China, June 30, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that two of its manufacturing facilities in Wuxi — Drug Substance Facility 2 (MFG2) and Drug Product Facility 1 (DP1) — together with its Drug Product Packaging Center (DPPC), have received GMP certification from Brazil's Agência Nacional...
EirGenix Showcases Dual-Track Biosimilars and CDMO Strategy in U.S. Market Push at BIO 2026
SAN DIEGO, June 30, 2026 /PRNewswire/ -- At BIO 2026, EirGenix presented its comprehensive HER2-positive breast cancer biosimilar portfolio and highlighted its integrated one-stop contract development and manufacturing organization (CDMO) service platform. The company actively pursued U.S. market opportunities through business matchmaking and global partnership discussions. While antibody-drug conjugates, other oncology and immunology biologics, and biosimilars continue to...
New Echelon Insights Survey Commissioned by Rockefeller Foundation: Most Americans Back Foreign Aid a Year After USAID’s End
A majority (54%) across the political spectrum remains favorable toward foreign aid a year after USAID's dismantlement, and 8 in 10 say the path forward is to reform and strengthen foreign aid — not eliminate it. Seven in ten Americans — including half of those who primarily support Trump over the Republican Party — would support spending...
